The lawsuit follows a cease-and-desist request and argues Lilly is using “deceptive” ads to claim its GLP-1 products are broadly superior to Novo’s medicines. Lilly countered that its campaign is ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results